Prodigiosin down-regulates survivin to facilitate paclitaxel sensitization in human breast carcinoma cell lines

Tsing Fen Ho, Yu Ta Peng, Show Mei Chuang, Shin Chang Lin, Bo Lin Feng, Chien Hsing Lu, Wan Ju Yu, Jo Shu Chang, Chia Che Chang

Research output: Contribution to journalArticlepeer-review

50 Citations (Scopus)


Prodigiosin is a bacterial metabolite with potent anticancer activity, which is attributed to its proapoptotic effect selectively active in malignant cells. Still, the molecular mechanisms whereby prodigiosin induces apoptosis remain largely unknown. In particular, the role of survivin, a vital inhibitor of apoptosis, in prodigiosin-induced apoptosis has never been addressed before and hence was the primary goal of this study. Our results showed that prodigiosin dose-dependently induced down-regulation of survivin in multiple breast carcinoma cell lines, including MCF-7, T-47D and MDA-MB-231. This down-regulation is mainly regulated at the level of transcription, as prodigiosin reduced the levels of both survivin mRNA and survivin promoter activity but failed to rescue survivin expression when proteasome-mediated degradation is abolished. Importantly, overexpression of survivin rendered cells more resistant to prodigiosin, indicating an essential role of survivin down-regulation in prodigiosin-induced apoptosis. In addition, we found that prodigiosin synergistically enhanced cell death induced by paclitaxel, a chemotherapy drug known to up-regulate survivin that in turn confers its own resistance. This paclitaxel sensitization effect of prodigiosin is ascribed to the lowering of survivin expression, because prodigiosin was shown to counteract survivin induction by paclitaxel and, notably, the sensitization effect was severely abrogated in cells that overexpress survivin. Taken together, our results argue that down-regulation of survivin is an integral component mediating prodigiosin-induced apoptosis in human breast cancer cells, and further suggest the potential of prodigiosin to sensitize anticancer drugs, including paclitaxel, in the treatment of breast cancer.

Original languageEnglish
Pages (from-to)253-260
Number of pages8
JournalToxicology and Applied Pharmacology
Issue number2
Publication statusPublished - 2009 Mar 1

All Science Journal Classification (ASJC) codes

  • Toxicology
  • Pharmacology


Dive into the research topics of 'Prodigiosin down-regulates survivin to facilitate paclitaxel sensitization in human breast carcinoma cell lines'. Together they form a unique fingerprint.

Cite this